港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

恆瑞醫藥

55.150

+11.10025.20%

成交量：8,266.38萬

成交額：47.34億

市值：3,641.84億

市盈率：53.23

高：60.500

開：57.000

低：55.150

收：44.050

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

江蘇恆瑞醫藥股份有限公司藥品申請臨牀試驗默示許可獲受理

（創新驅動下的醫藥巨頭新徵程：恆瑞港股IPO啓航）

430億天價交易！中國創新藥隱形冠軍突襲全球，恆瑞醫藥之後的下一個神話？

价值事务所

恆瑞醫藥申請一種七氟烷的工業化製備方法專利，製得的七氟烷純度高

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01276"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":55.15,"timestamp":1747987708026,"preClose":44.05,"halted":0,"volume":82663811,"delay":0,"floatShares":224519800,"shares":6603522074,"eps":1.036,"marketStatus":"休市中","change":11.1,"latestTime":"05-23 16:08:28","open":57,"high":60.5,"low":55.15,"amount":4733500812,"amplitude":0.121453,"askPrice":55.5,"askSize":2200,"bidPrice":55.15,"bidSize":14200,"shortable":0,"etf":0,"ttmEps":1.036205539,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1748223000000},"marketStatusCode":7,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":44.05,"dividendRate":0.003941,"openAndCloseTimeList":[[1747963800000,1747972800000],[1747976400000,1747987200000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":54.5,"timestamp":1747983600000,"preClose":55.4,"halted":0,"volume":54184000,"delay":0,"premium":"-7.34"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":224519800,"roa":"8.99%","roe":"15.22%","lyrEps":1.036,"shares":6603522074,"dividePrice":0.218423,"high":60.5,"amplitude":0.121453,"preClose":44.05,"low":55.15,"week52Low":55.15,"pbRate":"7.10","psRate":"11.42","week52High":60.5,"institutionHeld":0,"latestPrice":55.15,"committee":0.731707,"eps":1.036,"divideRate":0.003961,"volume":82663811,"delay":0,"ttmEps":1.036205539,"open":57,"prevYearClose":44.05,"prevWeekClose":44.05,"prevMonthClose":44.05,"prevQuarterClose":44.05,"fiveDayClose":44.05,"twentyDayClose":44.05,"sixtyDayClose":44.05},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/01276\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538115196","title":"江蘇恆瑞醫藥股份有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2538115196","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538115196?lang=zh_tw&edition=fundamental","pubTime":"2025-05-25 12:26","pubTimestamp":1748147212,"startTime":"0","endTime":"0","summary":"5月25日，据CDE官网消息，江苏恒瑞医药股份有限公司联合申请药品“苹果酸法米替尼胶囊”，获得临床试验默示许可，受理号CXHL2500298。公示信息显示，药品“苹果酸法米替尼胶囊”适应症：本品联合SHR-A1811±阿得贝利单抗用于实体瘤的治疗。江苏恒瑞医药股份有限公司，成立于1997年，位于连云港市，是一家以从事医药制造业为主的企业。企业注册资本637900.2274万人民币，实缴资本6190万人民币。通过天眼查大数据分析，江苏恒瑞医药股份有限公司共对外投资了36家企业，参与招投标项目5000次，知识产权方面有商标信息396条，专利信息1517条，此外企业还拥有行政许可1563个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/25122650649614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","LU0405327494.USD","LU1064130708.USD","LU1064131003.USD","03347","BK0188","BK0012","BK0239","LU1328615791.USD","BK0028","LU2488822045.USD","LU2328871848.SGD","BK0196","01276","600276","BK0060","LU1969619763.USD","BK1583","LU0405327148.USD","BK0183","LU2148510915.USD","BK1141"],"gpt_icon":0},{"id":"2538896115","title":"（創新驅動下的醫藥巨頭新徵程：恆瑞港股IPO啓航）","url":"https://stock-news.laohu8.com/highlight/detail?id=2538896115","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538896115?lang=zh_tw&edition=fundamental","pubTime":"2025-05-25 11:20","pubTimestamp":1748143200,"startTime":"0","endTime":"0","summary":"中国报告大厅网讯，2025年5月23日，中国医药产业迎来历史性时刻——恒瑞医药正式登陆港交所。作为国内首个实现从仿制药向创新药全面转型的标杆企业，此次港股上市不仅为公司全球化布局注入新动能，更标志着中国医药行业在创新驱动下的高质量发展进入新阶段。这种全球化布局正推动恒瑞从国内领军者向国际参与者蜕变。总结来看，此次港股上市标志着恒瑞医药正式迈入资本全球化新阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505251139459764a15e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505251139459764a15e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1328615791.USD","BK0028","LU1064131003.USD","LU2328871848.SGD","BK0188","BK0183","LU1064130708.USD","LU0405327494.USD","01276","BK0239","LU2488822045.USD","BK0012","BK0196","600276","LU0405327148.USD","LU2148510915.USD","LU1969619763.USD","BK0060","159938"],"gpt_icon":0},{"id":"2537199929","title":"430億天價交易！中國創新藥隱形冠軍突襲全球，恆瑞醫藥之後的下一個神話？","url":"https://stock-news.laohu8.com/highlight/detail?id=2537199929","media":"价值事务所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537199929?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 20:58","pubTimestamp":1748091537,"startTime":"0","endTime":"0","summary":"之所以突然涨那么多，主要是近期港股三生制药又爆出一笔天价BD交易，把旗下一款双抗SSGJ707授权给了辉瑞。与国外制药巨头相比，中国药企弯道超车选择了双抗这个赛道。ADC同样也是国内药企的优势领域，除了百利天恒，今年稍早些时候科伦博泰旗下的芦康沙妥珠单抗获批上市，成为了首个获得完全批准上市的国产ADC药物。随着双抗+ADC的不断突破，中国创新药企在国际制药舞台上的地位将会越来越重要。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524221354a48addaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524221354a48addaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2148510915.USD","LU1969619763.USD","LU1328615791.USD","BK0239","LU0405327494.USD","LU2328871848.SGD","BK0188","LU0405327148.USD","BK0183","LU2488822045.USD","BK0196","LU1064131003.USD","BK0028","600276","LU1064130708.USD","BK0012","BK0060","01276","159992"],"gpt_icon":0},{"id":"2537196419","title":"恆瑞醫藥申請一種七氟烷的工業化製備方法專利，製得的七氟烷純度高","url":"https://stock-news.laohu8.com/highlight/detail?id=2537196419","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537196419?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 20:41","pubTimestamp":1748090492,"startTime":"0","endTime":"0","summary":"金融界2025年5月24日消息，国家知识产权局信息显示，江苏恒瑞医药股份有限公司;上海恒瑞医药有限公司申请一项名为“一种七氟烷的工业化制备方法”的专利，公开号CN120025235A，申请日期为2025年04月。专利摘要显示，本公开涉及一种七氟烷的工业化制备方法。本公开所述的制备方法制得的七氟烷纯度高，收率高，浪费少，有利于工业化生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/24204150645883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2148510915.USD","BK0012","BK0188","LU1064130708.USD","BK0196","BK0183","BK0060","LU0405327494.USD","LU2328871848.SGD","LU1064131003.USD","BK0028","BK0239","LU0405327148.USD","01276","LU2488822045.USD","LU1969619763.USD","LU1328615791.USD","600276"],"gpt_icon":1}],"pageSize":4,"totalPage":52,"pageCount":1,"totalSize":207,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.4091,"hold":0.2273,"sell":0.0455,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4091,"analysts":22,"updateTime":1743523200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-05-23","current":52.570963,"percent":0,"low":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"high":53.632028,"avg":53.101495,"sd":0.530532,"marketCap":390693388207.53},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53}],"updateTime":1748171518645}}}